Loss of SLCO1B3 drives taxane resistance in prostate cancer

BACKGROUND: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castration-resistant prostate cancer (mCRPC). However, resistance to taxanes is common. Our objective was to investigate mechanisms of taxane resistance in prostate cancer. METHODS: Two docetaxel-resistant p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: de Morrée, Ellen S, Böttcher, René, van Soest, Robert J, Aghai, Ashraf, de Ridder, Corrina M, Gibson, Alice A, Mathijssen, Ron HJ, Burger, Herman, Wiemer, Erik AC, Sparreboom, Alex, de Wit, Ronald, van Weerden, Wytske M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5023781/
https://ncbi.nlm.nih.gov/pubmed/27537383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.251
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados